12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MKC1106-MT: Phase I data

An open-label, U.S. Phase I trial in 18 patients with advanced melanoma showed that MKC1106-MT elevated antigen-specific T cells in the blood of >40% of patients. Also, all 4 patients with lymphatic metastatic...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >